false2021Q10001275187--05-31trueP2Y66100us-gaap:OtherLiabilitiesCurrentus-gaap:OtherLiabilitiesNoncurrentus-gaap:OtherAssetsNoncurrent00012751872020-06-012020-08-310001275187us-gaap:CommonStockMember2020-06-012020-08-310001275187ango:PreferredStockPurchaseRightsMember2020-06-012020-08-31xbrli:shares00012751872020-10-05iso4217:USD00012751872019-06-012019-08-31iso4217:USDxbrli:shares00012751872020-08-3100012751872020-05-3100012751872019-05-3100012751872019-08-310001275187us-gaap:CommonStockMember2020-05-310001275187us-gaap:AdditionalPaidInCapitalMember2020-05-310001275187us-gaap:RetainedEarningsMember2020-05-310001275187us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-05-310001275187us-gaap:TreasuryStockMember2020-05-310001275187us-gaap:RetainedEarningsMember2020-06-012020-08-310001275187us-gaap:CommonStockMemberus-gaap:RestrictedStockUnitsRSUMember2020-06-012020-08-310001275187us-gaap:AdditionalPaidInCapitalMemberus-gaap:RestrictedStockUnitsRSUMember2020-06-012020-08-310001275187us-gaap:RestrictedStockUnitsRSUMember2020-06-012020-08-310001275187us-gaap:CommonStockMember2020-06-012020-08-310001275187us-gaap:AdditionalPaidInCapitalMember2020-06-012020-08-310001275187us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-012020-08-310001275187us-gaap:CommonStockMember2020-08-310001275187us-gaap:AdditionalPaidInCapitalMember2020-08-310001275187us-gaap:RetainedEarningsMember2020-08-310001275187us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-08-310001275187us-gaap:TreasuryStockMember2020-08-310001275187us-gaap:CommonStockMember2019-05-310001275187us-gaap:AdditionalPaidInCapitalMember2019-05-310001275187us-gaap:RetainedEarningsMember2019-05-310001275187us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-05-310001275187us-gaap:TreasuryStockMember2019-05-310001275187us-gaap:RetainedEarningsMember2019-06-012019-08-310001275187us-gaap:CommonStockMember2019-06-012019-08-310001275187us-gaap:AdditionalPaidInCapitalMember2019-06-012019-08-310001275187us-gaap:CommonStockMemberus-gaap:RestrictedStockUnitsRSUMember2019-06-012019-08-310001275187us-gaap:AdditionalPaidInCapitalMemberus-gaap:RestrictedStockUnitsRSUMember2019-06-012019-08-310001275187us-gaap:RestrictedStockUnitsRSUMember2019-06-012019-08-310001275187us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-06-012019-08-310001275187us-gaap:CommonStockMember2019-08-310001275187us-gaap:AdditionalPaidInCapitalMember2019-08-310001275187us-gaap:RetainedEarningsMember2019-08-310001275187us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-08-310001275187us-gaap:TreasuryStockMember2019-08-310001275187ango:C3WaveTipLocationAssetMember2019-12-172019-12-170001275187ango:C3WaveTipLocationAssetMember2019-12-170001275187ango:C3WaveTipLocationAssetMemberus-gaap:TrademarksMember2019-12-170001275187ango:C3WaveTipLocationAssetMemberus-gaap:TechnologyBasedIntangibleAssetsMember2019-12-170001275187ango:EximoMedicalLtd.Member2019-10-022019-10-020001275187ango:EximoMedicalLtd.Member2019-10-020001275187ango:EximoMedicalLtd.Member2019-06-012020-05-310001275187ango:EximoMedicalLtd.Member2020-05-310001275187ango:EximoMedicalLtd.Memberus-gaap:TechnologyBasedIntangibleAssetsMember2020-05-310001275187ango:EximoMedicalLtd.Memberus-gaap:TechnologyBasedIntangibleAssetsMember2020-06-012020-08-310001275187ango:VascularInterventionsandTherapiesMembercountry:US2020-06-012020-08-310001275187ango:VascularInterventionsandTherapiesMemberus-gaap:NonUsMember2020-06-012020-08-310001275187ango:VascularInterventionsandTherapiesMember2020-06-012020-08-310001275187ango:VascularInterventionsandTherapiesMembercountry:US2019-06-012019-08-310001275187ango:VascularInterventionsandTherapiesMemberus-gaap:NonUsMember2019-06-012019-08-310001275187ango:VascularInterventionsandTherapiesMember2019-06-012019-08-310001275187ango:VascularAccessMembercountry:US2020-06-012020-08-310001275187us-gaap:NonUsMemberango:VascularAccessMember2020-06-012020-08-310001275187ango:VascularAccessMember2020-06-012020-08-310001275187ango:VascularAccessMembercountry:US2019-06-012019-08-310001275187us-gaap:NonUsMemberango:VascularAccessMember2019-06-012019-08-310001275187ango:VascularAccessMember2019-06-012019-08-310001275187ango:OncologyMembercountry:US2020-06-012020-08-310001275187us-gaap:NonUsMemberango:OncologyMember2020-06-012020-08-310001275187ango:OncologyMember2020-06-012020-08-310001275187ango:OncologyMembercountry:US2019-06-012019-08-310001275187us-gaap:NonUsMemberango:OncologyMember2019-06-012019-08-310001275187ango:OncologyMember2019-06-012019-08-310001275187country:US2020-06-012020-08-310001275187us-gaap:NonUsMember2020-06-012020-08-310001275187country:US2019-06-012019-08-310001275187us-gaap:NonUsMember2019-06-012019-08-310001275187srt:MinimumMember2020-06-012020-08-310001275187srt:MaximumMember2020-06-012020-08-31xbrli:pureango:segment0001275187ango:ProductTechnologiesMember2020-08-310001275187us-gaap:CustomerRelationshipsMember2020-08-310001275187us-gaap:TrademarksMember2020-08-310001275187us-gaap:LicenseAgreementTermsMember2020-08-310001275187ango:ProductTechnologiesMember2020-05-310001275187us-gaap:CustomerRelationshipsMember2020-05-310001275187us-gaap:TrademarksMember2020-05-310001275187us-gaap:LicenseAgreementTermsMember2020-05-310001275187us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2019-06-030001275187us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:BaseRateMembersrt:MinimumMember2020-06-012020-08-310001275187us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:BaseRateMembersrt:MaximumMember2020-06-012020-08-310001275187us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LondonInterbankOfferedRateLIBORMembersrt:MinimumMember2020-06-012020-08-310001275187us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LondonInterbankOfferedRateLIBORMembersrt:MaximumMember2020-06-012020-08-310001275187us-gaap:LineOfCreditMember2020-06-012020-08-310001275187us-gaap:LineOfCreditMembersrt:MinimumMember2020-06-012020-08-310001275187us-gaap:LineOfCreditMembersrt:MaximumMember2020-06-012020-08-31ango:covenant0001275187us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2020-06-012020-08-310001275187us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2020-08-310001275187ango:The2004PlanandEmployeeStockPurchasePlanMember2020-08-310001275187us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-08-310001275187us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-08-310001275187us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-08-310001275187us-gaap:FairValueMeasurementsRecurringMember2020-08-310001275187us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-05-310001275187us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-05-310001275187us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-05-310001275187us-gaap:FairValueMeasurementsRecurringMember2020-05-310001275187ango:RevenueBasedPaymentMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2020-08-310001275187ango:RevenueBasedPaymentMemberus-gaap:MeasurementInputDiscountRateMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2020-08-310001275187ango:RevenueBasedPaymentMemberus-gaap:FairValueInputsLevel3Memberango:MeasurementInputProbabilityofPaymentMemberus-gaap:FairValueMeasurementsRecurringMembersrt:MinimumMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2020-08-310001275187ango:RevenueBasedPaymentMemberus-gaap:FairValueInputsLevel3Memberango:MeasurementInputProbabilityofPaymentMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ValuationTechniqueDiscountedCashFlowMembersrt:MaximumMember2020-08-310001275187us-gaap:CostOfSalesMember2020-06-012020-08-310001275187us-gaap:CostOfSalesMember2019-06-012019-08-310001275187us-gaap:ResearchAndDevelopmentExpenseMember2020-06-012020-08-310001275187us-gaap:ResearchAndDevelopmentExpenseMember2019-06-012019-08-310001275187us-gaap:SellingAndMarketingExpenseMember2020-06-012020-08-310001275187us-gaap:SellingAndMarketingExpenseMember2019-06-012019-08-310001275187us-gaap:GeneralAndAdministrativeExpenseMember2020-06-012020-08-310001275187us-gaap:GeneralAndAdministrativeExpenseMember2019-06-012019-08-31ango:Petition0001275187ango:CrBardIncMember2012-01-112012-01-11ango:claim0001275187ango:TheUtahActionMember2012-01-112012-01-110001275187ango:TheUtahActionMember2012-01-11ango:reexamination_appeal0001275187ango:TheUtahActionMember2016-03-112016-03-110001275187ango:TheUtahActionMember2016-03-110001275187ango:TheUtahActionMember2016-03-242016-03-240001275187ango:TheUtahActionMember2016-03-240001275187ango:TheUtahActionMember2016-03-292016-03-290001275187ango:TheUtahActionMemberango:C.R.BardInc.Memberus-gaap:PendingLitigationMember2016-03-302017-01-310001275187ango:MedCompandSmithsPatentActionMemberango:C.R.BardInc.Member2019-11-04ango:patent0001275187ango:TheDelawareActionMember2019-03-072019-03-07ango:motion0001275187ango:TheDelawareActionMember2015-06-012015-06-010001275187ango:ConstructionIssuesMember2020-08-310001275187ango:MerzNorthAmericaSettlementMember2019-06-282019-06-280001275187ango:LegalCostsMember2020-06-012020-08-310001275187ango:LegalCostsMember2019-06-012019-08-310001275187ango:MergersandAcquisitionsMember2020-06-012020-08-310001275187ango:MergersandAcquisitionsMember2019-06-012019-08-310001275187ango:TransitionserviceagreementMember2020-06-012020-08-310001275187ango:TransitionserviceagreementMember2019-06-012019-08-310001275187ango:DivestitureMember2020-06-012020-08-310001275187ango:DivestitureMember2019-06-012019-08-310001275187us-gaap:RestructuringChargesMember2020-06-012020-08-310001275187us-gaap:RestructuringChargesMember2019-06-012019-08-310001275187us-gaap:OtherExpenseMember2020-06-012020-08-310001275187us-gaap:OtherExpenseMember2019-06-012019-08-310001275187ango:BiolitecBankruptcyMember2019-06-012019-08-310001275187us-gaap:AccumulatedTranslationAdjustmentMember2020-05-310001275187us-gaap:AccumulatedTranslationAdjustmentMember2020-06-012020-08-310001275187us-gaap:AccumulatedTranslationAdjustmentMember2020-08-31
    
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended August 31, 2020
OR
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                  to                 
Commission file number 0-50761

AngioDynamics, Inc.
(Exact name of registrant as specified in its charter)
ANGO-20200831_G1.GIF
 

Delaware 11-3146460
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)

14 Plaza Drive, Latham, New York 12110
(Address of principal executive offices and zip code)
(518) 795-1400
Registrant’s telephone number, including area code
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading symbol Name of each exchange on which registered
Common stock, par value $.01 ANGO NASDAQ Global Select Market
Preferred Stock Purchase Rights NASDAQ Global Select Market

Securities registered pursuant to Section 12(g) of the Act:
None

(Title of Class)
 
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes  ☐    No  ☒
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.    Yes  ☐    No  ☒
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer   ☐    Accelerated filer   ☒
Non-accelerated filer   ☐ Smaller reporting company   ☐
Emerging growth company ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No  ☒
Indicate the number of shares outstanding of each of the Issuer’s classes of common stock, as of the latest practicable date.
Class   Outstanding as of October 5, 2020
Common Stock, par value $.01   37,953,078



AngioDynamics, Inc. and Subsidiaries
TABLE OF CONTENTS
 
Page
Item 1.
3
4
5
6
7
8
Item 2.
22
Item 3.
29
Item 4.
30
Item 1.
31
Item 1A.
33
Item 2.
34
Item 3.
34
Item 4.
34
Item 5.
34
Item 6.
35

2
PART 1. FINANCIAL INFORMATION
Item 1. Financial Statements.

AngioDynamics, Inc. and Subsidiaries
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(in thousands of dollars, except per share data)
 
Three Months Ended
Aug 31, 2020 Aug 31, 2019
Net sales $ 70,216  $ 66,042 
Cost of sales (exclusive of intangible amortization) 34,452  27,825 
Gross profit 35,764  38,217 
Operating expenses:
Research and development 9,009  6,292 
Sales and marketing 17,705  19,380 
General and administrative 8,557  8,453 
Amortization of intangibles 4,953  3,868 
Change in fair value of contingent consideration (657) (448)
Acquisition, restructuring and other items, net 1,319  1,500 
Total operating expenses 40,886  39,045 
Operating loss (5,122) (828)
Other income (expense):
Interest expense, net (215) (465)
Other income (expense), net 524  (98)
Total other income (expense), net 309  (563)
Loss before income tax benefit (4,813) (1,391)
Income tax benefit (545) (116)
Net loss $ (4,268) $ (1,275)
Loss per share
Basic $ (0.11) $ (0.03)
Diluted $ (0.11) $ (0.03)
Weighted average shares outstanding
Basic 38,157  37,783 
Diluted 38,157  37,783 
The accompanying notes are an integral part of these consolidated financial statements.
3
AngioDynamics, Inc. and Subsidiaries
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(unaudited)
(in thousands of dollars)
 
Three Months Ended
Aug 31, 2020 Aug 31, 2019
Net loss $ (4,268) $ (1,275)
Other comprehensive income (loss), before tax:
Foreign currency translation 2,095  (151)
Other comprehensive income (loss), before tax 2,095  (151)
Income tax expense related to items of other comprehensive income (loss) —  — 
Other comprehensive income (loss), net of tax 2,095  (151)
Total comprehensive loss, net of tax $ (2,173) $ (1,426)
The accompanying notes are an integral part of these consolidated financial statements.

4
AngioDynamics, Inc. and Subsidiaries

CONSOLIDATED BALANCE SHEETS
(unaudited)
(in thousands of dollars, except share data)
Aug 31, 2020 May 31, 2020
Assets
Current assets
Cash and cash equivalents $ 47,929  $ 54,435 
Accounts receivable, net of allowances of $2,373 and $2,150 respectively
33,590  31,263 
Inventories 52,762  59,905 
Prepaid expenses and other 7,957  7,310 
Total current assets 142,238  152,913 
Property, plant and equipment, net 29,427  28,312 
Other assets 16,833  15,338 
Intangible assets, net 194,318  197,136 
Goodwill 200,943  200,515 
Total assets $ 583,759  $ 594,214 
Liabilities and stockholders' equity
Current liabilities
Accounts payable $ 14,008  $ 19,096 
Accrued liabilities 23,587  29,380 
Current portion of contingent consideration —  836 
Other current liabilities 2,251  2,133 
Total current liabilities 39,846  51,445 
Long-term debt, net of current portion 40,000  40,000 
Deferred income taxes 23,817  24,057 
Contingent consideration, net of current portion 14,994  14,811 
Other long-term liabilities 10,048  9,029 
Total liabilities 128,705  139,342 
Commitments and contingencies (Note 14)
Stockholders' equity
Preferred stock, par value $0.01 per share, 5,000,000 shares authorized; no shares issued and outstanding
—  — 
Common stock, par value $0.01 per share, 75,000,000 shares authorized; 38,693,078 and 38,448,536 shares issued and 38,323,078 and 38,078,536 shares outstanding at August 31, 2020 and May 31, 2020, respectively
375  374 
Additional paid-in capital 564,225  561,871 
Accumulated deficit (104,586) (100,318)
Treasury stock, 370,000 shares at August 31, 2020 and May 31, 2020, respectively
(5,714) (5,714)
Accumulated other comprehensive income (loss) 754  (1,341)
Total Stockholders’ Equity 455,054  454,872 
Total Liabilities and Stockholders' Equity $ 583,759  $ 594,214 
The accompanying notes are an integral part of these consolidated financial statements.
5
AngioDynamics, Inc. and Subsidiaries
CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(in thousands of dollars)
Three Months Ended
Aug 31, 2020 Aug 31, 2019
Cash flows from operating activities:
Net loss $ (4,268) $ (1,275)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization 6,577  5,207 
Non-cash lease expense 666  — 
Stock based compensation 1,864  1,984 
Change in fair value of contingent consideration (657) (448)
Deferred income taxes (620) (175)
Change in accounts receivable allowances 460  (453)
Fixed and intangible asset impairments and disposals 90  99 
              Write-off of other assets —  593 
Other (432) (8)
Changes in operating assets and liabilities:
Accounts receivable (2,706) 11,474 
Inventories 7,247  (5,153)
Prepaid expenses and other (3,559) (746)
Accounts payable, accrued and other liabilities (10,087) (17,633)
Net cash used in operating activities (5,425) (6,534)
Cash flows from investing activities:
Additions to property, plant and equipment (1,824) (1,391)
Acquisition of intangibles —  (150)
Net cash used in investing activities (1,824) (1,541)
Cash flows from financing activities:
Repayment of long-term debt —  (132,500)
Deferred financing costs on long-term debt —  (741)
Payment of acquisition related contingent consideration —  (1,208)
Proceeds (outlays) from exercise of stock options and employee stock purchase plan 491  (1,300)
Net cash provided by (used in) financing activities 491  (135,749)
Effect of exchange rate changes on cash and cash equivalents 252  (168)
Decrease in cash and cash equivalents (6,506) (143,992)
Cash and cash equivalents at beginning of period 54,435  227,641 
Cash and cash equivalents at end of period $ 47,929  $ 83,649 
Supplemental disclosure of non-cash investing and financing activities:
Accrual for capital expenditures incurred during the period $ 197  $ 477 
The accompanying notes are an integral part of these consolidated financial statements.
6
AngioDynamics, Inc. and Subsidiaries
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(unaudited)
(in thousands of dollars, except share data)

 
Common Stock Additional
paid in
capital 		Accumulated deficit Accumulated
other
comprehensive
income (loss) 		Treasury Stock
Shares Amount Shares Amount Total
Balance at May 31, 2020 38,448,536  $ 374  $ 561,871  $ (100,318) $ (1,341) (370,000) $ (5,714) $ 454,872 
Net loss (4,268) (4,268)
Issuance/Cancellation of restricted stock units 164,946  (143) (143)
Purchases of common stock under ESPP 79,596  1  633  634 
Stock-based compensation 1,864  1,864 
Other comprehensive income, net of tax 2,095  2,095 
Balance at August 31, 2020
38,693,078  $ 375  $ 564,225  $ (104,586) $ 754  (370,000) $ (5,714) $ 455,054 



Common Stock Additional
paid in
capital 		Retained earnings Accumulated
other
comprehensive
loss 		Treasury Stock
Shares Amount Shares Amount Total
Balance at May 31, 2019 37,984,382  $ 372  $ 555,040  $ 66,469  $ (1,352) (370,000) $ (5,714) $ 614,815 
Net loss (1,275) (1,275)
Exercise of stock options 48,136  1  530  531 
Issuance/Cancellation of restricted stock units 287,087  (2,459) (2,459)
Purchases of common stock under ESPP 40,270  628  628 
Stock-based compensation 1,984  1,984 
Other comprehensive loss, net of tax (151) (151)
Balance at August 31, 2019
38,359,875  $ 373  $ 555,723  $ 65,194  $ (1,503) (370,000) $ (5,714) $ 614,073 

The accompanying notes are an integral part of these consolidated financial statements.
7
AngioDynamics, Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
1. CONSOLIDATED FINANCIAL STATEMENTS
The Consolidated Balance Sheet as of August 31, 2020, the Consolidated Statements of Operations and the Consolidated Statements of Comprehensive Loss for the three months ended August 31, 2020 and August 31, 2019, the Consolidated Statements of Stockholders’ Equity for the three months ended August 31, 2020 and August 31, 2019 and the Consolidated Statements of Cash Flows for the three months ended August 31, 2020 and August 31, 2019 have been prepared by the Company and are unaudited. The Consolidated Balance Sheet as of May 31, 2020 was derived from audited consolidated financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America. In the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary to state fairly the financial position, changes in stockholders’ equity and comprehensive income, results of operations and cash flows as of and for the period ended August 31, 2020 (and for all periods presented) have been made.
The unaudited interim consolidated financial statements for the three months ended August 31, 2020 and August 31, 2019 include the accounts of AngioDynamics, Inc. and its wholly owned subsidiaries, collectively, the “Company”. All intercompany balances and transactions have been eliminated.
2. ACQUISITIONS
C3 Wave Tip Location Acquisition
On December 17, 2019, the Company acquired the C3 Wave tip location asset from Medical Components Inc. for an aggregate purchase price of $10.0 million with $5.0 million of potential future contingent consideration related to technical milestones. This acquisition fills a gap in the Vascular Access portfolio and supports the Company's strategic plan. The Company accounted for this acquisition as an asset purchase. The Company recorded the amount paid at closing as inventory of $0.6 million and intangible assets of a trademark of $0.9 million and product technology of $8.5 million. The intangible assets will be amortized over 15 years. The contingent consideration is comprised of technical milestones and will be accounted for when the contingency is resolved or becomes probable and reasonably estimable.
Eximo Acquisition
On October 2, 2019, the Company entered into a share purchase agreement to acquire Eximo Medical, Ltd., a pre-commercial stage medical device company and its proprietary 355nm B Laser Atherectomy technology. The aggregate purchase price of $60.7 million included an upfront payment of $45.8 million and contingent consideration with an estimated fair value of $14.9 million. This acquisition expands and complements the Company’s Vascular Interventions and Therapies product portfolio by adding the 355nm B Laser Atherectomy technology which treats Peripheral Artery Disease.
The Company accounted for the Eximo acquisition under the acquisition method of accounting for business combinations. Accordingly, the cost to acquire the assets was allocated to the underlying net assets in proportion to estimates of their respective fair values. The excess of the purchase price over the estimated fair value of the net assets acquired was recorded as goodwill. Goodwill is non-deductible for income tax purposes.
The Company has not disclosed the amount of revenue and earnings for sales of Eximo products since acquisition, nor proforma information, because these amounts are not significant to the Company's financial statements. Acquisition-related costs associated with the Eximo acquisition, which are included in "acquisition, restructuring and other items, net" in the accompanying Consolidated Statements of Operations, were approximately $0.6 million in fiscal year 2020. The following table summarizes the final aggregate purchase price allocated to the net assets acquired:
8
(in thousands) Final allocation
Accounts receivable $ 50 
Inventory 150 
Prepaid and other current assets 54 
Long-term deposits 51 
Property, plant and equipment 397 
Intangible assets:
Product technology 60,300 
Goodwill 11,427 
Total assets acquired $ 72,429 
Liabilities assumed
Accounts payable $ 84 
Other current liabilities 615 
Deferred tax liabilities 11,070 
Total liabilities assumed $ 11,769 
Net assets acquired $ 60,660 

The Company finalized the allocation of the purchase price to the assets acquired and liabilities assumed in the fourth quarter of fiscal year 2020.
The value assigned to the product technology was derived using the multi-period excess earnings method under the income approach. This approach estimates the excess earnings generated over the lives of the customers that existed as of the acquisition date and discounts such earnings to present value. The product technology is deemed to have a useful life of fifteen years and will be amortized on a straight-line basis over the useful life.
The goodwill arising from the acquisition consists largely of synergies and economies of scale the Company hopes to achieve from combining the acquired assets with the Company's current operations.
3. REVENUE FROM CONTRACTS WITH CUSTOMERS

Revenue Recognition

Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.
The Company has one primary revenue stream which is the sales of its products.
Disaggregation of Revenue
The following tables summarize net product revenue by Global Business Unit ("GBU") and geography:
Three Months Ended Aug 31, 2020
Three Months Ended Aug 31, 2019
(in thousands) United States International Total United States International Total
Net sales
Vascular Interventions & Therapies $ 26,981  $ 2,876  $ 29,857  $ 25,676  $ 3,237  $ 28,913 
Vascular Access 19,222  8,883  28,105  19,284  3,875  $ 23,159 
Oncology 7,905  4,349  12,254  7,977  5,993  $ 13,970 
Total $ 54,108  $ 16,108  $ 70,216  $ 52,937  $ 13,105  $ 66,042 

9
Net Product Revenue
The Company's products consist of a wide range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company's devices are generally used in minimally invasive, image-guided procedures. Most of the Company's products are intended to be used once and then discarded, or they may be implanted for short or long term use. The Company sells its products to its distribution partners and to end users, such as interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists and critical care nurses.
Contracts and Performance Obligations
The Company contracts with its customers based on customer purchase orders, which in many cases are governed by master purchasing agreements. The Company’s contracts with customers are generally for product only, and do not include other performance obligations such as services or other material rights. As part of its assessment of each contract, the Company evaluates certain factors including the customer’s ability to pay (or credit risk). For each contract, the Company considers the promise to transfer products, each of which is distinct, to be the identified performance obligations.
Transaction Price and Allocation to Performance Obligations
Transaction prices of products are typically based on contracted rates. Product revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products to a customer. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method. As such, revenue is recorded net of rebates, returns and other deductions.
If a contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products underlying each performance obligation. The Company has standard pricing for its products and determines standalone selling prices based on the price at which the performance obligation is sold separately.
Revenue Recognition
Revenue is recognized when control of the product is transferred to the customer (i.e., when the Company’s performance obligation is satisfied), which occurs at a point in time, and may be upon shipment from the Company’s manufacturing site or delivery to the customer’s named location, based on the contractual shipping terms of a contract.
In determining whether control has transferred, the Company considers if there is a present right to payment from the customer and when physical possession, legal title and risks and rewards of ownership have transferred to the customer.
The Company typically invoices customers upon satisfaction of identified performance obligations. As the Company’s standard payment terms are 30 to 90 days from invoicing, the Company does not provide any significant financing to its customers.
Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue.
Variable Consideration
Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established for discounts, returns, rebates and allowances that are offered within contracts between the Company and its customers. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as a contra asset.
Rebates and Allowances: The Company provides certain customers with rebates and allowances that are explicitly stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. The Company establishes a liability for such amounts, which is included in accrued expenses in the accompanying Consolidated Balance Sheets. These rebates and allowances result from performance-based offers that are primarily based on attaining contractually specified sales volumes and administrative fees the Company is required to pay to group purchasing organizations.
Product Returns: The Company generally offers customers a limited right of return. Product returns after 30 days must be pre-approved by the Company and customers may be subject to a 20% restocking charge. To be accepted, a returned product
10
must be unadulterated, undamaged and have at least twelve months remaining prior to its expiration date. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product return liabilities using its historical product return information and considers other factors that it believes could significantly impact its expected returns, including product recalls. During the three months ended August 31, 2020, such product returns were not material.
Contract Balances with Customers
A receivable is recognized in the period the Company ships the product. Payment terms on invoiced amounts are based on contractual terms with each customer and generally coincide with revenue recognition. Accordingly, the Company does not have any contract assets associated with the future right to invoice its customers. In some cases, if control of the product has not yet transferred to the customer or the timing of the payments made by the customer precedes the Company’s fulfillment of the performance obligation, the Company recognizes a contract liability that is included in deferred revenue in the accompanying Consolidated Balance Sheets.
The following table presents changes in the Company’s receivables, contract assets and contract liabilities with customers:
(in thousands) Aug 31, 2020
May 31, 2020
Receivables $ 33,590  $ 31,263 
Contract assets $ —  $ — 
Contract liabilities $ 595  $ 545 
During the three months ended August 31, 2020, the Company had additions to contract liabilities of $0.4 million. This was offset by $0.4 million in revenue that was recognized during the three months ended August 31, 2020.
Costs to Obtain or Fulfill a Customer Contract
Under ASC 606, the Company recognizes an asset for incremental costs of obtaining a contract with a customer if it expects to recover those costs. The Company’s sales incentive compensation plans qualify for capitalization since these plans are directly related to sales achieved during a period of time. However, the Company has elected the practical expedient under ASC 340-40-25-4 to expense the costs as they are incurred within selling and marketing expenses since the amortization period is less than one year.
The Company accounts for shipping and handling activities related to contracts with customers as costs to fulfill the promise to transfer the associated products. Shipping and handling costs, associated with the distribution of finished products to customers, are recorded in costs of goods sold and are recognized when the related finished product is shipped to the customer. Amounts charged to customers for shipping are recorded in net sales.

4. INVENTORIES
Inventories are stated at lower of cost and net realizable value (using the first-in, first-out method). Inventories consisted of the following:
(in thousands) Aug 31, 2020 May 31, 2020
Raw materials $ 22,858  $ 23,308 
Work in process 8,133  8,318 
Finished goods 21,771  28,279 
Inventories $ 52,762  $ 59,905 
The Company periodically reviews for both obsolescence and loss of value. The Company makes assumptions about the future demand for and market value of the inventory. Based on these assumptions, the Company estimates the amount of obsolete, expiring and slow moving inventory. The total inventory reserve at August 31, 2020 and May 31, 2020 was $4.4 million and $4.7 million, respectively.
5. GOODWILL AND INTANGIBLE ASSETS
Intangible assets other than goodwill are amortized over their estimated useful lives on either a straight-line basis or proportionately to the benefit being realized. Useful lives range from two to eighteen years. The Company periodically reviews the estimated useful lives of its intangible assets and reviews such assets or asset groups for impairment whenever events or changes in circumstances indicate that the carrying value of the assets or asset groups may not be recoverable. If an intangible
11
asset or asset group is considered to be impaired, the amount of the impairment will equal the excess of the carrying value over the fair value of the asset.
Goodwill is not amortized, but rather, is tested for impairment annually or more frequently if impairment indicators arise. Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in each business combination.
The Company's annual testing for impairment of goodwill was completed as of December 31, 2019. The Company operates as a single operating segment with one reporting unit and consequently evaluates goodwill for impairment based on an evaluation of the fair value of the Company as a whole. The Company determines the fair value of the reporting unit based on the market valuation approach and concluded that it was not more-likely-than-not that the fair value of the Company's reporting unit was less than its carrying value as of December 31, 2019. In the fourth quarter of fiscal year 2020, the Company concluded that the sustained decline in its market capitalization represented an impairment indicator that required the Company to perform an interim test for goodwill impairment as of May 31, 2020 and the Company recorded a goodwill impairment charge of $158.6 million as of May 31, 2020 to write down the carrying value of the reporting unit to fair value.
The future occurrence of another potential indicator of impairment, such as a significant adverse change in legal, regulatory, business or economic conditions or a more-likely-than-not expectation that the reporting unit or a significant portion of the reporting unit will be sold or disposed of, would require another interim assessment for the reporting unit prior to the next required annual assessment as of December 31, 2020.
There were no adjustments to goodwill for the three months ended August 31, 2020 other than foreign currency translation adjustments.
Intangible assets consisted of the following:
Aug 31, 2020
(in thousands) Gross carrying value Accumulated amortization Net carrying value
Product technologies $ 253,833  $ (92,425) $ 161,408 
Customer relationships 60,257  (31,119) 29,138 
Trademarks 10,150  (6,771) 3,379 
Licenses 6,087  (5,694) 393 
$ 330,327  $ (136,009) $ 194,318 

May 31, 2020
(in thousands) Gross carrying value Accumulated amortization Net carrying value
Product technologies $ 251,569  $ (88,547) $ 163,022 
Customer relationships 60,160  (30,018) 30,142 
Trademarks 10,150  (6,691) 3,459 
Licenses 6,087  (5,574) 513 
$ 327,966  $ (130,830) $ 197,136 
Amortization expense for the three months ended August 31, 2020 and August 31, 2019 was $5.0 million and $3.9 million, respectively.
Expected future amortization expense related to the intangible assets is as follows:
(in thousands)
Remainder of 2021 $ 13,753 
2022 17,588 
2023 17,488 
2024 15,870 
2025 16,625 
2026 and thereafter 112,994 
$ 194,318 
12

6. ACCRUED LIABILITIES
Accrued liabilities consisted of the following: 
(in thousands) Aug 31, 2020 May 31, 2020
Payroll and related expenses $ 6,844  $ 13,059 
Royalties 1,425  2,392 
Accrued severance 1,253  794 
Sales and franchise taxes 812  634 
Outside services 2,400  2,222 
Indemnification holdback 5,000  5,000 
Other 5,853  5,279 
$ 23,587  $ 29,380 

7. LONG TERM DEBT
On June 3, 2019 and in connection with the completion of the Fluid Management divestiture, the Company repaid all amounts outstanding under its existing Credit Agreement and entered into a new Credit Agreement with the lenders party thereto, JPMorgan Chase Bank, N.A., as administrative agent, and Bank of America, N.A. and KeyBank National Association, as co-syndication agents.
The Credit Agreement provides for a $125.0 million secured revolving credit facility (the “Revolving Facility”), which includes an uncommitted expansion feature that allows the Company to increase the total revolving commitments and/or add new tranches of term loans in an aggregate amount not to exceed $75.0 million.  The proceeds may be used to refinance certain existing indebtedness of the Company and its subsidiaries, to finance the working capital needs, and for general corporate purposes (including permitted acquisitions), of the Company and its subsidiaries.
The Credit Agreement has a five year maturity. Interest on the facility will be based, at the Company’s option, on a base rate of LIBOR plus an applicable margin tied to the Company’s total leverage ratio and having ranges between 0.25% and 0.75% for base rate loans and between 1.25% and 1.75% for LIBOR loans. After default, the interest rate may be increased by 2.0%. The facility will also carry a commitment fee of 0.20% to 0.25% per annum on the unused portion.
The Company's obligations under the Revolving Facility are unconditionally guaranteed, jointly and severally, by the Company's material direct and indirect domestic subsidiaries (the “Guarantors”). All obligations of the Company and the Guarantors under the Revolving Facility are secured by first priority security interests in substantially all of the assets of the Company and the Guarantors.
The Credit Agreement includes customary representations, warranties and covenants, and acceleration, indemnity and events of default provisions, including, among other things, two quarterly financial covenants as follows: 
•maximum leverage ratio of consolidated total indebtedness* to consolidated EBITDA* of not greater than 3.00 to 1.00 (during certain periods following material acquisitions the ratio shall be increased to 3.50 to 1.00).
•fixed charge coverage ratio of consolidated EBITDA minus consolidated capital expenditures to consolidated interest expense paid or payable in cash plus scheduled principal payments in respect of indebtedness under the Credit Agreement of not less than 1.25 to 1.00.
* The definitions of consolidated total indebtedness and consolidated EBITDA are maintained in the credit agreement included as an exhibit to Form 8-k filed on June 6, 2019.
As of August 31, 2020, there was $40.0 million outstanding balance on the Revolving Facility. As of August 31, 2020 and May 31, 2020, the carrying value of long-term debt approximated its fair market value.
The interest rate on the Revolving Facility at August 31, 2020 was 1.41%.
The Company was in compliance with the Credit Agreement covenants as of August 31, 2020.

13

8. INCOME TAXES
The Company provides for income taxes at the end of each interim period based on the estimated effective tax rate for the full fiscal year adjusted for any discrete events, which are recorded in the period that they occur.  The estimated annual effective tax rate prior to discrete items was 14.2% as of the first quarter of fiscal year 2021, as compared to 8.3% for the same period in fiscal year 2020. In fiscal year 2021, the Company’s effective tax rate differs from the U.S. statutory rate primarily due to the impact of the valuation allowance, foreign taxes, and other non-deductible permanent items (such as non-deductible meals and entertainment, Section 162(m) excess compensation and non-deductible share based compensation).
The Company regularly assesses its ability to realize its deferred tax assets. Assessing the realization of deferred tax assets requires significant management judgment. In determining whether its deferred tax assets are more likely than not realizable, the Company evaluated all available positive and negative evidence, and weighted the evidence based on its objectivity. Evidence that the Company considered included its history of net operating losses, which resulted in the Company recording a full valuation allowance for its deferred tax assets in fiscal year 2016, except the naked credit deferred tax liability.
Based on the review of all available evidence, the Company determined that it has not yet attained a sustained level of profitability and the objectively verifiable negative evidence outweighed the positive evidence. Therefore, the Company has provided a valuation allowance on its federal and state net operating loss carryforwards, federal and state R&D credit carryforwards and other net deferred tax assets that have a limited life and are not supportable by the naked credit deferred tax liability sourced income as of August 31, 2020. The Company will continue to assess the level of the valuation allowance required. If sufficient positive evidence exists in future periods to support a release of some or all of the valuation allowance, such a release would likely have a material impact on the Company’s results of operations.

9. SHARE-BASED COMPENSATION
The Company has two stock-based compensation plans that provide for the issuance of up to approximately 11.3 million shares of common stock. The 2004 Stock and Incentive Award Plan (the "2004 Plan") provides for the grant of incentive options to the Company's employees and for the grant of non-statutory stock options, restricted stock, stock appreciation rights, performance units, performance shares and other incentive awards to the Company's employees, directors and other service providers. The Company also has an employee stock purchase plan.
For the three months ended August 31, 2020 and August 31, 2019, share-based compensation expense was $1.9 million and $2.0 million, respectively.
During the three months ended August 31, 2020 and August 31, 2019, the Company granted stock options and restricted stock units under the 2004 Plan to certain employees and members of the Board of Directors. Stock option awards are valued using the Black-Scholes option-pricing model and then amortized on a straight-line basis over the requisite service period of the award. Restricted stock unit awards are valued based on the closing trading value of the Company's shares on the date of grant and then amortized on a straight-line basis over the requisite service period of the award.
As of August 31, 2020, there was $15.3 million of unrecognized compensation expense related to share-based payment arrangements. These costs are expected to be recognized over a weighted-average period of approximately four years. The Company has sufficient shares to satisfy expected share-based payment arrangements.
10. EARNINGS PER SHARE
Basic earnings per share is based on the weighted average number of common shares outstanding without consideration of potential common stock. Diluted earnings per share includes the dilutive effect of potential common stock consisting of stock options, restricted stock units and performance stock units, provided that the inclusion of such securities is not anti-dilutive. In periods with a net loss, stock options and restricted stock units are not included in the computation of diluted loss per share as the impact would be anti-dilutive.

14
The following table reconciles basic to diluted weighted-average shares outstanding:
Three Months Ended
(in thousands) Aug 31, 2020 Aug 31, 2019
Basic 38,157  37,783 
Effect of dilutive securities —  — 
Diluted 38,157  37,783 
Securities excluded as their inclusion would be anti-dilutive 3,180  2,503 

11. SEGMENT AND GEOGRAPHIC INFORMATION
The Company considers the business to be a single operating segment engaged in the development, manufacture and sale of medical devices for vascular access, peripheral vascular disease and oncology on a global basis. The Company's chief operating decision maker, the President and Chief Executive Officer (CEO), evaluates the various global product portfolios on a net sales basis. Executives reporting to the CEO include those responsible for commercial operations, manufacturing operations, regulatory and quality and certain corporate functions. The CEO evaluates profitability, investment and cash flow metrics on a consolidated worldwide basis due to shared infrastructure and resources.
The table below summarizes net sales by Global Business Unit: 
Three Months Ended
(in thousands) Aug 31, 2020 Aug 31, 2019
Net sales
Vascular Interventions & Therapies 
$ 29,857  $ 28,913 
Vascular Access 28,105  23,159 
Oncology 12,254  13,970 
Total $ 70,216  $ 66,042 
The table below presents net sales by geographic area based on external customer location:
Three Months Ended
(in thousands) Aug 31, 2020 Aug 31, 2019
Net sales
United States $ 54,108  $ 52,937 
International 16,108  13,105 
Total $ 70,216  $ 66,042 

12. FAIR VALUE
On a recurring basis, the Company measures certain financial assets and financial liabilities at fair value based upon quoted market prices, where available. Where quoted market prices or other observable inputs are not available, the Company applies valuation techniques to estimate fair value. FASB ASC Topic 820, Fair Value Measurements and Disclosures, establishes a three-level valuation hierarchy for disclosure of fair value measurements. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:
•Level 1 - Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.

•Level 2 - Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.

•Level 3 - Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.
15
The Company's financial instruments include cash and cash equivalents, accounts receivable, accounts payable and contingent consideration. The carrying amount of cash and cash equivalents, accounts receivable, and accounts payable approximates fair value due to the immediate or short-term maturities. The Company's recurring fair value measurements using significant unobservable inputs (Level 3) relate to contingent consideration liabilities.
The following tables provide information by level for assets and liabilities that are measured at fair value on a recurring basis:
Fair Value Measurements using inputs considered as:
Fair Value at Aug 31, 2020
(in thousands) Level 1 Level 2 Level 3
Financial Liabilities
Contingent consideration for acquisition earn outs $ —  $ —  $ 14,994  $ 14,994 
Total Financial Liabilities $ —  $ —  $ 14,994  $ 14,994 
Fair Value Measurements using inputs considered as: Fair Value at May 31, 2020
(in thousands) Level 1 Level 2 Level 3
Financial Liabilities
Contingent consideration for acquisition earn outs $ —  $ —  $ 15,647  $ 15,647 
Total Financial Liabilities $ —  $ —  $ 15,647  $ 15,647 

There were no transfers between Level 1, 2 and 3 for the three months ended August 31, 2020.
The table below presents the changes in fair value components of Level 3 instruments:
Three Months Ended Aug 31, 2020
(in thousands) Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
Balance, May 31, 2020
$ 15,647 
Total gains or losses (realized/unrealized):
Change in present value of contingent consideration (1) (657)
Currency gain from remeasurement 4 
Balance, August 31, 2020
$ 14,994 
(1) Change in the fair value of contingent consideration is included in earnings and comprised of changes in estimated earn out payments based on projections of Company performance and amortization of the present value discount.

Contingent Consideration for Acquisition Earn Outs
Some of the Company's business combinations involve the potential for the payment of future contingent consideration upon the achievement of certain product development milestones or various other performance conditions. Payment of the additional consideration is generally contingent on the acquired company reaching certain performance milestones, including attaining specified revenue levels or product development targets. Contingent consideration is recorded at the estimated fair value of the contingent payments on the acquisition date. The fair value of the contingent consideration is remeasured at the estimated fair value at each reporting period with the change in fair value recognized as income or expense within change in fair value of contingent consideration in the Consolidated Statements of Operations.
The Company measures the initial liability and remeasures the liability on a recurring basis using Level 3 inputs as defined under authoritative guidance for fair value measurements. The fair value is determined using a discounted cash flow model applied to projected net sales, using probabilities of achieving projected net sales and projected payment dates. Projected net sales are based on the Company's internal projections and extensive analysis of the target market and the sales potential. Increases or decreases in any valuation inputs in isolation may result in a significantly lower or higher fair value measurement in the future.
16
The recurring Level 3 fair value measurements of the contingent consideration liabilities include the following significant unobservable inputs as of August 31, 2020:
(in thousands) Fair Value Valuation Technique Unobservable Input Range
Revenue based payments $ 14,994  Discounted cash flow Discount rate 5%
Probability of payment 66% - 100%
Projected fiscal year of payment 2024 - 2025

At August 31, 2020, the range of estimated potential undiscounted future contingent consideration that the Company expects to pay as a result of all completed acquisitions is $20.0 million. The revenue projections milestones associated with the contingent consideration must be reached in future periods ranging from fiscal years 2021 to 2029 in order for the associated consideration to be paid.
13. LEASES
The Company determines if an arrangement is a lease at inception of the contract. The Company has operating leases for buildings, primarily for office space, R&D, manufacturing and warehousing.
Operating lease right-of-use (“ROU”) assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. Many of the lease agreements contain renewal or termination clauses that are factored into the determination of the lease term if it is reasonably certain that these options would be exercised. The Company recognizes lease expense for these leases on a straight-line basis over the lease term.
The following table presents supplemental balance sheet information related to leases:
(in thousands) Balance Sheet Location Aug 31, 2020 May 31, 2020
Assets
Operating lease ROU asset Other assets $ 9,990  $ 10,146 
Liabilities
Current operating lease liabilities Other current liabilities 2,174  2,077 
Non-current operating lease liabilities Other long-term liabilities 8,178  8,345 
Total lease liabilities $ 10,352  $ 10,422 

The interest rate implicit in lease agreements is typically not readily determinable, and as such the Company used the incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The incremental borrowing rate is defined as the interest the Company would pay to borrow on a collateralized basis, considering factors such as length of lease term. The following table presents the weighted average remaining lease term and discount rate:
Aug 31, 2020
Weighted average remaining term (in years) 4.74
Weighted average discount rate 4.1  %

17
The following table presents the maturities of the lease liabilities:
(in thousands) Aug 31, 2020
Remainder of 2021 $ 1,927 
2022 2,484 
2023 2,532 
2024 1,984 
2025 1,259 
2026 and thereafter 1,188 
Total lease payments $ 11,374 
Less: Imputed Interest 1,022 
Total lease obligations $ 10,352 
Less: Current portion of lease obligations 2,174 
Long-term lease obligations $ 8,178 
During the three months ended August 31, 2020 and 2019, the Company recognized $0.9 million and $0.6 million of operating lease expense, respectively, which includes immaterial short-term leases. The expenses on the Consolidated Statement of Operations were classified as follows:
(in thousands)
Aug 31, 2020
Aug 31, 2019
Cost of sales $ 201  $ 270 
Research and development 288  — 
Sales and marketing 100  98 
General and administrative 295  272 
$ 884  $ 640 

The following table presents supplemental cash flow and other information related to leases for the three months ended:
(in thousands) Aug 31, 2020 Aug 31, 2019
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases $ 672  $ 563 
ROU assets obtained in exchange for lease liabilities
Operating leases $ 487  $ — 

14. COMMITMENTS AND CONTINGENCIES    
Legal Proceedings
The Company is involved in various legal proceedings, including commercial, intellectual property, product liability, and regulatory matters of a nature considered normal for its business. The Company accrues for amounts related to these matters if it is probable that a liability has been incurred, and an amount can be reasonably estimated. The Company discloses such matters when there is at least a reasonable possibility that a material loss may have been incurred. However, the Company cannot predict the outcome of any litigation or the potential for future litigation.
C.R. Bard, Inc. v. AngioDynamics, Inc.
On January 11, 2012, C.R. Bard, Inc. (“Bard”) filed a suit in the United States District Court of Utah claiming certain of the Company's implantable port products infringe on three U.S. patents held by Bard (the "Utah Action"). Bard’s complaint sought unspecified damages and other relief. The Company filed petitions for reexamination in the US Patent and Trademark Office ("USPTO") seeking to invalidate all three patents asserted by Bard in the litigation. The Company's petitions were granted and 40 of Bard's 41 patent claims were rejected and, following further proceedings, the Patent Office issued a Final Rejection of all 40 claims subject to reexamination. Thereafter, Bard filed appeals to the USPTO Board of Appeals and Interferences for all three reexaminations which were decided as follows: For US Patent No. 7,785,302, the rejections of six of the ten claims under reexamination were affirmed, but were reversed on four of the ten claims. For U.S. Patent No. 7,959,615
18
the rejections of eight of the ten claims under reexamination were affirmed but the rejections of the other two of the ten claims were reversed. In the third, for U.S. Patent No. 7,947,022 the rejections of all twenty claims under reexamination were affirmed. Thereafter, Bard sought Rehearing in all three appeals and the Company sought Rehearing in the ‘302 and ‘615 appeals. The USPTO denied all three Rehearing Requests, but modified its characterization of one prior art reference for the ‘302 and ‘022 decisions. 
Bard filed appeals to the Federal Circuit Court of Appeals in all three reexams and the Company Cross-Appealed for the ‘302 and the ‘615 reexams.  MedComp also filed an Amicus Brief in support of the Company on November 22, 2017.  Meanwhile, on July 12, 2017 Bard assigned the asserted patents to Bard Peripheral Vascular, Inc. (“BPV”) which was added as co-Appellant before the Federal Circuit and as a co-Plaintiff in the Utah action. An oral hearing was held on September 5, 2018 and the Court rendered its decision on September 28, 2018, affirming that claims 1-5 and 10 of the ‘615 patent were invalid, but that claims 6-7 of the 615 patent and claims 1-4 of the 302 patent were valid over the prior art references considered in the Reexamination proceedings.  The Federal Circuit also reversed the PTAB’s claim construction ruling and remanded for consideration of obviousness for the remaining claims under the new claim construction ruling and for further findings with respect to whether one of the asserted references qualified as a printed publication.  On January 28, 2019, on remand, the USPTO reversed the rejections of the ‘302 claims 1-10, ‘022 claims 1-20 and ‘615 claims 8-9.  The USPTO has since issued Inter Partes Reexamination Certificates for the ‘302 Patent for the ‘022 patent and for the ‘615 patent. The Company thereafter filed a Motion to Unstay the Utah Case and that motion was granted. On November 4, 2019 the Court held a joint Status Conference among the Company’s Utah Action and two other cases filed by Bard on the same patents against MedComp and Smiths. The Court set a schedule for defendant's Motions to Dismiss or Transfer. The Company filed its motion on November 25, 2019; and Bard filed a responsive brief and a motion for venue discovery on December 9, 2019. The Company filed a responsive brief on December 16, 2019 and Bard filed a reply on December 23, 2019. On February 27, 2020, the Court referred all non-dispositive motions to the presiding Magistrate and on March 3, 2020 the Court granted Bard’s Motion for Venue Discovery and denied the Company’s transfer motion without prejudice to re-filing after completion of the venue discovery, but no later than June 30, 2020. The parties have since engaged in venue discovery and AngioDynamics re-filed its Motion to Dismiss or Transfer on June 30, 2020. Bard filed an opposition brief on July 28, 2020, and the Company filed a subsequent reply. The Company believes these claims are without merit and intends to defend them vigorously.  The Company has not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable.
On March 10, 2015, Bard and BPV filed suit in the United States District Court for the District of Delaware (the “Delaware Action") claiming certain of the Company's implantable port products infringe on three other U.S. patents held by Bard, which are different from those asserted in the Utah action. Bard's complaint seeks unspecified damages and other relief. On June 1, 2015, the Company filed two motions in response to Bard’s Complaint - one sought transfer to the District of Utah where the Utah Action is currently pending, and the other sought dismissal of the entire complaint on grounds that none of the claims in the asserted patents is directed to patent eligible subject matter under Section 101 of the Patent Statute and in light of recent authority from the U. S. Supreme Court.
On January 12, 2016, the Court issued a decision denying both motions. A Markman hearing was held on March 10, 2017 and the Court issued its Claim Construction Order on May 19, 2017. On May 19, 2017, Bard served its Final Infringement Contentions and on June 2, 2017, the Company served its Final Invalidity Contentions.
On October 20, 2017, the scheduling order for the case was amended to, among other things, set a trial date commencing July 23, 2018. The parties completed Expert Discovery in January 2018 and completed briefing on their respective case dispositive motions on April 27, 2018. On June 26, 2018, the Court denied all case dispositive motions, ruling that issues of material fact remained in dispute. On July 9, 2018, the Court continued the trial until March 2019. On January 9, 2019 the Court held a further claim construction hearing to resolve two outstanding claim construction issues prior to trial. A Report and Recommendation (by Magistrate-Judge Fallon) was issued on February 11, 2019 and entered by the Court on February 28, 2019. Jury selection was held on Friday March 1, 2019 and trial began on March 4, 2019.  On day four of the jury trial, at the close of C.R. Bard’s case, the Court granted the Company's oral motion for judgment as a matter of law under rule 50(a) as well as its motions for summary judgement on the grounds that the asserted patents are invalid, ineligible, not infringed and not willfully infringed.  On April 5, 2019, Bard filed a precautionary Notice of Appeal to the Federal Circuit. On April 26, 2019, the District Court issued a Memorandum and Order confirming the grant of judgment in the Company’s favor of patent ineligibility, non-infringement, patent invalidity and no willful infringement. Meanwhile, on May 10, 2019, the Company filed a Motion for Attorney fees and non-taxable expenses under 35 USC Sec. 285. On May 21, 2019, the Court issued a Memorandum and Order which, inter alia, stayed proceedings on the Company’s fee Motion and the Company’s equitable claims pending appeal; and entered Final Judgment on May 21, 2019 as well. Bard filed a second Notice of Appeal on May 23, 2019. Both appeals have since been consolidated and Bard’s opening brief was filed on September 27, 2019; the Company's answering brief was filed on January 15, 2020; and Bard’s reply brief was filed on March 4, 2020. A hearing was held on June 1, 2020, and the Company is currently awaiting a decision from the Federal Circuit . The Company maintains its belief that
19
Bard’s claims are without merit. The Company has not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable.
AngioDynamics, Inc. v. C.R. Bard, Inc.
On May 30, 2017, the Company commenced an action in the United States District Court for the Northern District of New York entitled AngioDynamics, Inc. v. C.R. Bard, Inc. and Bard Access Systems, Inc. (“Bard”).  In this action, the Company alleges that Bard has illegally tied the sales of its tip location systems to the sales of its PICCs.  The Company alleges that this practice violates the federal antitrust laws and has had, and continues to have, an anti-competitive effect in the market for PICCs.  The Company seeks both monetary damages and injunctive relief. Bard moved to dismiss on September 8, 2017. On August 6, 2018 the court denied Bard’s motion in its entirety.  Discovery is largely complete, summary judgment, including all reply briefs, were fully briefed in October 2020, and the case will subsequently proceed to trial thereafter.
Merz North America Settlement
On May 16, 2019, Merz North America, Inc. (“Merz”) commenced an action in the United States District Court for the Southern District of New York entitled Merz North America, Inc. v. AngioDynamics, Inc.  In this action, Merz alleged breach of contract against AngioDynamics based on a March 1, 2016 Distribution Agreement.  On June 28, 2019, AngioDynamics reached a settlement with Merz. AngioDynamics made a lump-sum payment of $2.5 million to Merz in return for dismissal of the case with prejudice during the first quarter of fiscal year 2020.  The case was subsequently dismissed.

15. ACQUISITION, RESTRUCTURING, AND OTHER ITEMS, NET
Acquisition, Restructuring and Other Items
Acquisition, restructuring and other items, net consisted of:
Three Months Ended
(in thousands) Aug 31, 2020 Aug 31, 2019
Legal (1)
$ 794  $ 669 
Mergers and acquisitions (2)
1  246 
Transition service agreement (3)
(375) (737)
Divestiture (4)
273  758 
Restructuring —  26 
Other 626  538 
Total $ 1,319  $ 1,500 
(1) Legal expenses related to litigation that is outside the normal course of business.
(2) Mergers and acquisitions expenses related to investment banking, legal and due diligence.
(3) Transition services agreement that was entered into as a result of the sale of the Fluid Management business.
(4) Divestiture expenses incurred to transition manufacturing from Glens Falls, NY to Queensbury, NY.

Included in the $0.7 million in legal for the three months ended August 31, 2019 is a $0.4 million settlement received for the Biolitec bankruptcy litigation. The settlement received offsets legal expenses paid related to the settlement proceedings.

16. ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)
Changes in each component of accumulated other comprehensive income (loss), net of tax, are as follows:
Three Months Ended Aug 31, 2020
(in thousands) Foreign currency translation income(loss)
Balance at May 31, 2020
$ (1,341)
Other comprehensive income before reclassifications, net of tax 2,095 
Amounts reclassified from accumulated other comprehensive loss — 
Net other comprehensive income $ 2,095 
Balance at August 31, 2020
$ 754 
20

17. RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
The following table provides a description of recent accounting pronouncements that may have a material effect on the Company's consolidated financial statements:
Recently Issued Accounting Pronouncements - Adopted
Standard Description Date Adopted Effect on the Consolidated Financial Statements
ASU 2018-13, Fair Value Measurement (Topic 820)
This ASU removes, modifies and adds various disclosure requirements related to fair value disclosures. Disclosures related to transfers between fair value hierarchy levels will be removed and further detail around changes in unrealized gains and losses for the period and unobservable inputs used in determining level 3 fair value measurements will be added, among other changes. June 1, 2020 The Company adopted the new standard in the first quarter of fiscal year 2021 and it did not have an impact on the Company's consolidated financial statements.
ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments
This ASU replaces the current incurred loss impairment methodology for financial assets measured at amortized cost with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information, including forecasted information, to develop credit loss estimates. June 1, 2020 The Company adopted the new standard in the first quarter of fiscal year 2021 and it did not have an impact on the Company's consolidated financial statements.

Recently Issued Accounting Pronouncements - Not Yet Applicable or Adopted

There are no other new accounting pronouncements issued that are expected to have a material impact on our consolidated financial statements.
21
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.
The following information should be read together with the consolidated financial statements and the notes thereto and other information included elsewhere in this quarterly report on Form 10-Q.
Forward-Looking Statements
This quarterly report on Form 10-Q, including the sections entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from our expectations. Factors that may affect our actual results achieved include, without limitation, our ability to develop existing and new products, future actions by FDA or other regulatory agencies, results of pending or future clinical trials, the results of ongoing litigation, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, our ability to integrate purchased businesses and other factors including natural disasters and pandemics (such as the scope, scale and duration of the impact of the novel coronavirus, COVID-19). Other risks and uncertainties include, but are not limited to, the factors described from time to time in our reports filed with the SEC.
Although we believe that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate and, therefore, there can be no assurance that the forward-looking statements included in this quarterly report on Form 10-Q will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by us or any other person that our objectives and plans will be achieved. Any forward-looking statements are made pursuant to the Private Securities Litigation Reform Act of 1995 and, as such, speak only as of the date made. AngioDynamics disclaims any obligation to update the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date stated, or if no date is stated, as of the date of this document.
Executive Overview
We design, manufacture and sell a wide range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Our devices are generally used in minimally invasive, image-guided procedures. Many of our products are intended to be used once and then discarded, or they may be temporarily implanted for short- or longer-term use.
Our business operations cross a variety of markets. Our financial performance is impacted by changing market dynamics, which have included an emergence of value-based purchasing by healthcare providers, consolidation of healthcare providers, the increased role of the consumer in health care decision-making and an aging population, among others. In addition, our growth is impacted by changes within our sector, such as the merging of competitors to gain scale and influence; changes in the regulatory environment for medical device; and fluctuations in the global economy.
Our sales and profitability growth also depends, in part, on the introduction of new and innovative products, together with ongoing enhancements to our existing products. Expansions to our product offerings are created through internal product development, technology licensing and strategic alliances. We recognize the importance of, and intend to continue to make investments in research and development activities and business development opportunities and feel confident that our existing capital structure and free cash flow generation will allow us to properly fund those activities.
We sell our products in the United States primarily through a direct sales force, and outside the U.S. through a combination of a direct sales and distributor relationships. We expect our businesses to grow in both sales and profitability through geographic expansion, market penetration, new product introductions and increasing our direct presence internationally.
The COVID-19 global pandemic may pose significant risks to our business. It is too early to quantify the impact this situation will have on fiscal year 2021 or beyond, but the public health actions being undertaken to reduce spread of the virus are causing and may continue to cause significant disruptions with respect to consumer demand, hospital operating procedures and workflow, our ability to continue to manufacture products and the reliability of our supply chain. Accordingly, management is evaluating the Company’s liquidity position, communicating with and monitoring the actions of our customers and suppliers,
22
and reviewing our near-term financial performance as we manage the Company through the uncertainty related to the coronavirus.
As of the date of this report:
•Our field based sales personnel have continued to re-enter the field in a safe and well orchestrated manner in order to once again provide unparalleled service to our physicians.
•Our Latham headquarters opened at the beginning of the first quarter of fiscal year 2021 in accordance with New York State guidelines. Our other office-based employees returned to the office during the first quarter of fiscal year 2021.
•Our manufacturing facility in Queensbury, New York is operating under our business continuity plan with precautions including, without limitation, creating small “work pods”, increasing distancing and regularly monitoring temperatures.
As discussed in more detail below, we will closely monitor our liquidity and capital resources through the disruption caused by the COVID-19 pandemic.
In evaluating the operating performance of our business, management focuses on revenue, gross margin, operating income, earnings per share and cash flow from operations. A summary of these key financial metrics for the three months ended August 31, 2020 compared to the three months ended August 31, 2019 are as follows:

•Revenue increased by 6.3% to $70.2 million.
•Gross margin decreased 700 bps to 50.9%.
•Operating loss increased by $4.3 million to $5.1 million.
•Loss per share increased by $0.08 to a loss of $0.11.
•Cash used in operations decreased by $1.1 million to $5.4 million.
The ongoing recovery from the COVID-19 pandemic has had a varying impact on each of our three businesses. Our Vascular Interventions & Therapies and Vascular Access businesses performed the strongest of the businesses during the quarter. The number of procedures improved from the COVID-19 lows in the second half of last fiscal year, but remain below pre-COVID-19 levels. Our Oncology business continued to face pressure from COVID-19 related procedure headwinds and a challenging capital spending environment. We continued our commitment to supporting and progressing our key growth initiatives (AngioVac, Auryon and NanoKnife), managing operating expenses and managing our cash and balance sheet.
New Accounting Pronouncements

Information regarding new accounting pronouncements is included in Note 17 to our consolidated financial statements in this Quarterly Report on Form 10-Q.
Results of Operations for the Three Months Ended August 31, 2020 and August 31, 2019
For the three months ended August 31, 2020, the Company reported a net loss of $4.3 million, or a loss of $0.11 per diluted share, on net sales of $70.2 million, compared with a net loss of $1.3 million, or a loss of $0.03 per diluted share, on net sales of $66.0 million during the same quarter of the prior year.
Net Sales

Net sales - Net sales are derived from the sale of products and related freight charges, less discounts and returns.

23
Three Months Ended
(in thousands) Aug 31, 2020 Aug 31, 2019 % Growth
Net Sales by Global Business Unit
       Vascular Interventions & Therapies $ 29,857  $ 28,913  3.3%
       Vascular Access 28,105  23,159  21.4%
       Oncology 12,254  13,970  (12.3)%
            Total $ 70,216  $ 66,042  6.3%
Net Sales by Geography
       United States $ 54,108  $ 52,937  2.2%
       International 16,108  13,105  22.9%
           Total $ 70,216  $ 66,042  6.3%
For the three months ended August 31, 2020, net sales increased $4.2 million to $70.2 million compared to the same period in the prior year.
Vascular Interventions & Therapies

•Total Vascular Interventions & Therapies sales increased $0.9 million primarily attributable to strong performance in the AngioVac business which grew $1.8 million. During the quarter, the Company continued to see strong case volumes in AngioVac, which increased 40% from the prior year. In addition, there was $1.1 million in sales of Auryon, which was acquired as part of the Eximo acquisition in the second quarter of fiscal year 2020. These increases were partially offset by lower volume in Venous products due to fewer elective procedures during the COVID-19 pandemic.
•U.S. Vascular Interventions & Therapies sales increased $1.3 million due to increased case volume in AngioVac, increased Core Peripheral product sales and $1.1 million in sales of Auryon. These increases were partially offset by decreased sales volume in Venous.
•International Vascular Interventions & Therapies sales decreased $0.4 million.

Vascular Access

•Total Vascular Access sales increased $4.9 million due to increased sales of PICCs and Midlines of $3.4 million and $2.2 million, respectively. These increases are the result of a large order in the United Kingdom related to the COVID-19 pandemic for $5.2 million along with the distribution agreement with MedComp. These increases were offset by decreased sales in Ports and Dialysis. BioFlo product lines comprise 59% of overall Vascular Access sales compared to 50% a year ago.
•U.S. Vascular Access sales decreased $0.1 million.
•International Vascular Access sales increased by $5.0 million primarily as a result of a large order in the United Kingdom related to the COVID-19 pandemic for $5.2 million

Oncology

•Total Oncology sales decreased $1.7 million year over year primarily due to lower NanoKnife capital sales of $1.0 million, decreased RadioFrequency Ablation sales of $0.6 million and decreased Balloon product sales of $0.5 million due to lower volumes. This was partially offset by increased Microwave sales of $0.3 million and BioSentry sales of $0.4 million.
•U.S. Oncology sales decreased by $0.1 million primarily due to decreased Balloon product sales of $0.5 million due to lower volumes. This was partially offset by increased Microwave disposable sales of $0.4 million, BioSentry sales of $0.4 million and NanoKnife disposable sales of $0.1 million.
•International Oncology sales decreased $1.6 million year over year as a result of decreased RadioFrequency Ablation and Microwave sales of $0.7 million and NanoKnife capital and disposable sales of $0.9 million.

The Company has discussed the ongoing transformation from a company with a broad portfolio of largely undifferentiated products to a more focused medical technology company that delivers unique and innovative health care solutions. This transformation enables the Company to move away from the mature, lower-growth markets where we have
24
competed in the past by carving out significant space in larger and faster growing markets. As such, the growth in the near to mid-term will be driven by our high technology platforms including AngioVac, Auryon and NanoKnife.

Gross Profit, Operating expenses, and Other income (expense)
Three Months Ended
(in thousands) Aug 31, 2020 Aug 31, 2019 % Change
Gross profit $ 35,764  $ 38,217  (6.4) %
Gross profit % of sales 50.9  % 57.9  %
Research and development $ 9,009  $ 6,292  43.2  %
% of sales 12.8  % 9.5  %
Selling and marketing $ 17,705  $ 19,380  (8.6) %
% of sales 25.2  % 29.3  %
General and administrative $ 8,557  $ 8,453  1.2  %
% of sales 12.2  % 12.8  %

Gross profit - Gross profit consists of net sales less the cost of goods sold, which includes the costs of materials, products purchased from third parties and sold by us, manufacturing personnel, royalties, freight, business insurance, depreciation of property and equipment and other manufacturing overhead, exclusive of intangible amortization.

Gross profit decreased by $2.5 million compared to the prior year. The decrease is primarily attributable to the following:
    
•Sales volume positively impacted gross profit by $3.0 million year over year.
•Net productivity negatively impacted gross profit by $3.0 million primarily as a result of under absorption of $2.2 million and costs associated with the COVID-19 pandemic of $0.4 million. The under absorption in manufacturing operations was due to the fact that the Company maintained staffing levels and continued producing product to provide flexibility during the uncertainty brought about by the COVID-19 pandemic.
•Mix negatively impacted gross margin by $1.4 million as a result of the large order in the United Kingdom for lower gross margin products and decreased NanoKnife capital sales. This was partially offset by increased AngioVac sales.
•A reserve for recalled products of $0.5 million and amortization of prior year capitalized variances of $0.4 million.

Research and development expenses - Research and development (“R&D”) expenses include internal and external costs to develop new products, enhance existing products, validate new and enhanced products, and manage clinical, regulatory and medical affairs.

R&D expense increased $2.7 million compared to the prior year. The increase is primarily attributable to the following:

•Research and development expenses related to AngioVac, NanoKnife and Tip Location increased $1.5 million along with $1.2 million of expenses related to Auryon.

Sales and marketing expenses - Sales and marketing (“S&M”) expenses consist primarily of salaries, commissions, travel and related business expenses, attendance at medical society meetings, product promotions and marketing activities.

S&M expense decreased $1.7 million compared to the prior year. The decrease is primarily attributable to the following:

•Travel expenses decreased $1.5 million due to less travel as a result of the COVID-19 pandemic. In addition, tradeshow and other expenses decreased $1.7 million due to the cancellation of events.
•Compensation and benefits decreased approximately $0.4 million which is primarily the result of decreased commissions.
•Expenses related to the build-out of the Auryon sales and marketing teams to prepare for full product launch of $2.1 million.

General and administrative expenses - General and administrative (“G&A”) expenses include executive management, finance, information technology, human resources, business development, legal, and the administrative and professional costs associated with those activities.

25
G&A expense increased $0.1 million compared to the prior year. The increase is primarily attributable to the following:

•Increased expenses related to the Auryon product to integrate the business of $0.2 million was partially offset by decreased travel and expenses of $0.1 million.
Three Months Ended
(in thousands) Aug 31, 2020 Aug 31, 2019 $ Change
Amortization of intangibles $ 4,953  $ 3,868  $ 1,085 
Change in fair value of contingent consideration $ (657) $ (448) $ (209)
Acquisition, restructuring and other items, net $ 1,319  $ 1,500  $ (181)
Other expense $ 309  $ (563) $ 872 

Amortization of intangibles - Represents the amount of amortization expense that was taken on intangibles assets held by the Company.

•Amortization expense increased $1.1 million compared to the prior year as a result of the Eximo Medical and C3 Wave tip location acquisitions, which increased intangible assets by $60.3 million and $9.4 million, respectively. These additions resulted in additional amortization expense of $1.2 million.

Change in fair value of contingent consideration - Represents changes in contingent consideration driven by changes to estimated future payments on earn-out liabilities created through acquisitions and amortization of present value discounts on long-term contingent consideration.

•The change from the prior year is due to a decision to no longer pursue the final RadiaDyne technical milestone, which resulted in a reduction in the liability of $0.8 million. This reduction in the fair value was offset by normal amortization of the present value of the remaining Eximo contingent consideration of $14.9 million recorded in the second quarter of fiscal year 2020.

Acquisition, restructuring and other items, net - Represents costs associated with mergers and acquisitions, restructuring expenses, legal costs that are related to litigation that is not in the ordinary course of business, legal settlements and other one-time items.

Acquisition, restructuring and other items, net decreased by $0.2 million compared to the prior year. The decrease is primarily attributable to the following:

•Legal expense, related to litigation that is outside of the normal course of business, of $0.8 million was recorded in the first quarter of fiscal year 2021 compared to $0.7 million in the prior year.
•There was no M&A expense incurred in the first quarter of fiscal year 2021 compared to $0.2 million in the prior year.
•In the first quarter of fiscal year 2021, the Company incurred $0.3 million of expense to move manufacturing facilities as a result of the sale of the Fluid Management business compared to $0.8 million in the prior year.
•As part of the sale of the Fluid Management business, the Company entered into a transition services agreement with Medline for certain legal, human resource, tax, accounting and information technology services from the Company for a period not to exceed 24 months. As a result of the transition services agreement, the Company invoiced Medline $0.4 million in the first quarter of fiscal year 2021.
•Other expenses of $0.6 million in the first quarter of fiscal year 2021 consists of expenses to move the manufacturing of BioSentry products and severance associated with the sale of the Fluid Management business, compared to $0.5 million in the prior year.

Other expenses, net - Other expenses include interest expense, foreign currency impacts, bank fees, and amortization of deferred financing costs.

•The increase in other income from the prior year of $0.9 million is primarily due to foreign currency unrealized gains of $0.6 million and the prior year write-off of deferred financing fees associated with the old Credit Facility of $0.6 million. This was partially offset by increased interest expense of $0.1 million due on the $40.0 million outstanding on the Revolving Facility at the end of the first quarter of fiscal year 2021 compared to no debt outstanding in the prior year. In addition, interest income decreased by $0.2 million as a result of less cash on hand at the end of the first quarter of fiscal year 2021.
26

Income Tax Provision (Benefit)
Three Months Ended
(in thousands) Aug 31, 2020 Aug 31, 2019
Income tax expense (benefit) $ (0.5) $ (0.1)
Effective tax rate including discrete items 11.3  % 8.3  %

Our effective tax rate including discrete items for the three month periods ended August 31, 2020 and August 31, 2019 was 11.3% and 8.3%, respectively. In fiscal year 2021, the Company’s effective tax rate differs from the U.S. statutory rate primarily due to the impact of the valuation allowance, foreign taxes, and other non-deductible permanent items (such as non-deductible meals and entertainment, Section 162(m) excess compensation and non-deductible share based compensation).
The estimated annual effective tax rate, however, prior to discrete items was 14.2% in the first quarter of fiscal year 2021, as compared to 8.3% for the same period in fiscal year 2020.     
Liquidity and Capital Resources
We are continuously and critically reviewing our liquidity and anticipated capital requirements in light of the significant uncertainty created by the COVID-19 global pandemic. We believe that our current cash on hand and availability under our revolving credit facility provide sufficient liquidity to meet our anticipated needs for capital for at least the next 12 months. We are closely monitoring receivables and payables. In addition, we believe that our recently increased inventory levels provide additional risk mitigation in the event we incur a manufacturing disruption.
Our cash and cash equivalents totaled $47.9 million as of August 31, 2020, compared with $54.4 million as of May 31, 2020. As of August 31, 2020 and May 31, 2020, total debt outstanding related to the Revolving Facility was $40.0 million. The fair value of contingent consideration liability as of August 31, 2020 and May 31, 2020, was $15.0 million and $15.6 million, respectively.
The table below summarizes our cash flows:
Three Months Ended
(in thousands) Aug 31, 2020 Aug 31, 2019
Cash used in:
Operating activities $ (5,425) $ (6,534)
Investing activities (1,824) (1,541)
Financing activities 491  (135,749)
Effect of exchange rate changes on cash and cash equivalents 252  (168)
Net change in cash and cash equivalents $ (6,506) $ (143,992)
Cash flows consisted of the following:
Cash used in operating activities
Three months ended August 31, 2020:
•Net loss of $4.3 million plus the non-cash items, primarily driven by depreciation and amortization and share based compensation, contributed to cash used in operations of $5.4 million.
•Working capital was negatively impacted by increased accounts receivable of $2.7 million and decreased accounts payable and accrued liabilities of $10.1 million. Inventory had a favorable impact of $7.2 million on working capital.
Three months ended August 31, 2019:
•Net loss of $1.3 million plus the non-cash items, primarily driven by depreciation and amortization, contributed to cash used in operations of $6.5 million.
•Working capital was negatively impacted by increased inventory on hand of $5.2 million and decreased accounts payable and accrued liabilities of $17.6 million. Accounts receivable had a favorable impact on working capital as a result of the sale of the Fluid Management business.
27

Cash used in investing activities
Three months ended August 31, 2020 and August 31, 2019:
•$1.8 million in fixed asset additions versus $1.4 million in the prior year.
Cash provided by (used in) financing activities
Three months ended August 31, 2020 and August 31, 2019:
•$132.5 million repayment of long-term debt in conjunction with the new Credit Agreement that was entered into at the beginning of the first quarter of fiscal year 2020. Refer to Note 7 of the financial statements.
•$0.5 million of proceeds from stock option and ESPP activity versus $1.3 million in outlays in the prior year.
•$1.2 million payment on earn-out liabilities in the prior year.
On June 3, 2019 and in connection with the completion of the Fluid Management divestiture, the Company repaid all amounts outstanding under its existing Credit Agreement and entered into a new Credit Agreement. The Credit Agreement provides for a $125.0 million secured Revolving Facility, which includes an uncommitted expansion feature that allows the Company to increase the total revolving commitments and/or add new tranches of term loans in an aggregate amount not to exceed $75.0 million.  The Credit Agreement includes customary representations, warranties and covenants, and acceleration, indemnity and events of default provisions, including, among other things, two financial covenants. One financial covenant requires us to maintain a fixed charge coverage ratio of not less than 1.25 to 1.00. The other financial covenant requires us to maintain a total leverage ratio of not greater than 3.00 to 1.00. The total leverage ratio is based upon our trailing twelve months total adjusted EBITDA (as defined in the Credit Agreement). The amount that we can borrow under our Credit Agreement is directly based on our leverage ratio.
On December 17, 2019, the Company made a $15.0 million draw on the Revolving Facility as part of the acquisition of the C3 Wave tip location asset from Medical Components Inc. that is described Note 2 to the financial statements. In the fourth quarter of fiscal year 2020, the Company made an additional $25.0 million draw on the Revolving Facility. We believe that our current cash balance, together with cash generated from operations and access to our Revolving Facility, will provide sufficient liquidity to meet our anticipated needs for capital for at least the next 12 months. If we seek to make significant acquisitions of other businesses or technologies in the future for cash, we may require external financing.
28
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
Foreign Currency Exchange Rate Risk
We are exposed to market risk from changes in currency exchange rates, as well as interest rate fluctuations on our credit facility and investments that could impact our results of operations and financial position.
We transact sales in currencies other than the U.S. Dollar, particularly the Euro, British pound and Canadian dollar. Approximately 6% of our sales in the first quarter of fiscal year 2021 were denominated in foreign currencies. We do not have expenses denominated in foreign currencies at the level of our sales and as a result, our profitability is exposed to currency fluctuations. When the U.S. Dollar strengthens, our sales and gross profit will be negatively impacted. In addition, we have assets and liabilities denominated in non-functional currencies which are remeasured at each reporting period, with the offset to changes presented as a component of Other (Expenses) Income. Significant non-functional balances include accounts receivable due from a sub-section of our international customers.
Interest Rate Risk
On June 3, 2019, we entered into the Credit Agreement which provides for a $125 million Revolving Facility. Interest on the facility will be based, at the Company’s option, on a base rate of LIBOR plus an applicable margin tied to the Company’s total leverage ratio and having ranges between 0.25% and 0.75% for base rate loans and between 1.25% and 1.75% for LIBOR loans. In the event of default, the interest rate may be increased by 2.0%. As of August 31, 2020 there was $40.0 million outstanding on the Revolving Facility.
Concentration of Credit Risk
Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents, our credit facility and trade accounts receivable.
The Company maintains cash and cash equivalents at various institutions and performs periodic evaluations of the relative credit standings of these financial institutions to ensure their credit worthiness. In addition, the Credit Agreement is structured across five above investment grade banks. The Company has the ability to draw equally amongst the five banks which limits the concentration of credit risk of one institution.
Concentration of credit risk with respect to trade accounts receivable is limited due to the large number of customers that purchase products from the Company. No single customer represents more than 10% of total sales. The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business. Although the Company does not currently foresee a significant credit risk associated with the outstanding accounts receivable, repayment is dependent upon the financial stability of our customers.
29
Item 4. Controls and Procedures.
Evaluation of disclosure controls and procedures
As of the end of the period covered by this report, our management, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rule 13a-15(b) of the Securities Exchange Act of 1934, as amended. Based on that evaluation, the Chief Executive Officer and the Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report were effective to provide reasonable assurance that the information required to be disclosed by us in reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms and is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control over Financial Reporting
There was no change in our internal control over financial reporting for the fiscal quarter ended August 31, 2020 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

30
AngioDynamics, Inc. and Subsidiaries
PART II: OTHER INFORMATION

Item 1. Legal Proceedings.
The Company is involved in various legal proceedings, including commercial, intellectual property, product liability, and regulatory matters of a nature considered normal for its business. The Company accrues for amounts related to these matters if it is probable that a liability has been incurred, and an amount can be reasonably estimated. The Company discloses such matters when there is at least a reasonable possibility that a material loss may have been incurred. However, the Company cannot predict the outcome of any litigation or the potential for future litigation.
C.R. Bard, Inc. v. AngioDynamics, Inc.
On January 11, 2012, C.R. Bard, Inc. (“Bard”) filed a suit in the United States District Court of Utah claiming certain of the Company's implantable port products infringe on three U.S. patents held by Bard (the "Utah Action"). Bard’s complaint sought unspecified damages and other relief. The Company filed petitions for reexamination in the US Patent and Trademark Office ("USPTO") seeking to invalidate all three patents asserted by Bard in the litigation. The Company's petitions were granted and 40 of Bard's 41 patent claims were rejected and, following further proceedings, the Patent Office issued a Final Rejection of all 40 claims subject to reexamination. Thereafter, Bard filed appeals to the USPTO Board of Appeals and Interferences for all three reexaminations which were decided as follows: For US Patent No. 7,785,302, the rejections of six of the ten claims under reexamination were affirmed, but were reversed on four of the ten claims. For U.S. Patent No. 7,959,615 the rejections of eight of the ten claims under reexamination were affirmed but the rejections of the other two of the ten claims were reversed. In the third, for U.S. Patent No. 7,947,022 the rejections of all twenty claims under reexamination were affirmed. Thereafter, Bard sought Rehearing in all three appeals and the Company sought Rehearing in the ‘302 and ‘615 appeals. The USPTO denied all three Rehearing Requests, but modified its characterization of one prior art reference for the ‘302 and ‘022 decisions. 
Bard filed appeals to the Federal Circuit Court of Appeals in all three reexams and the Company Cross-Appealed for the ‘302 and the ‘615 reexams.  MedComp also filed an Amicus Brief in support of the Company on November 22, 2017.  Meanwhile, on July 12, 2017 Bard assigned the asserted patents to Bard Peripheral Vascular, Inc. (“BPV”) which was added as co-Appellant before the Federal Circuit and as a co-Plaintiff in the Utah action. An oral hearing was held on September 5, 2018 and the Court rendered its decision on September 28, 2018, affirming that claims 1-5 and 10 of the ‘615 patent were invalid, but that claims 6-7 of the 615 patent and claims 1-4 of the 302 patent were valid over the prior art references considered in the Reexamination proceedings.  The Federal Circuit also reversed the PTAB’s claim construction ruling and remanded for consideration of obviousness for the remaining claims under the new claim construction ruling and for further findings with respect to whether one of the asserted references qualified as a printed publication.  On January 28, 2019, on remand, the USPTO reversed the rejections of the ‘302 claims 1-10, ‘022 claims 1-20 and ‘615 claims 8-9.  The USPTO has since issued Inter Partes Reexamination Certificates for the ‘302 Patent for the ‘022 patent and for the ‘615 patent. The Company thereafter filed a Motion to Unstay the Utah Case and that motion was granted. On November 4, 2019 the Court held a joint Status Conference among the Company’s Utah Action and two other cases filed by Bard on the same patents against MedComp and Smiths. The Court set a schedule for defendant's Motions to Dismiss or Transfer. The Company filed its motion on November 25, 2019; and Bard filed a responsive brief and a motion for venue discovery on December 9, 2019. The Company filed a responsive brief on December 16, 2019 and Bard filed a reply on December 23, 2019. On February 27, 2020, the Court referred all non-dispositive motions to the presiding Magistrate and on March 3, 2020 the Court granted Bard’s Motion for Venue Discovery and denied the Company’s transfer motion without prejudice to re-filing after completion of the venue discovery, but no later than June 30, 2020. The parties have since engaged in venue discovery and AngioDynamics re-filed its Motion to Dismiss or Transfer on June 30, 2020. Bard filed an opposition brief on July 28, 2020, and the Company filed a subsequent reply. The Company believes these claims are without merit and intends to defend them vigorously.  The Company has not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable.
On March 10, 2015, Bard and BPV filed suit in the United States District Court for the District of Delaware (the “Delaware Action") claiming certain of the Company's implantable port products infringe on three other U.S. patents held by Bard, which are different from those asserted in the Utah action. Bard's complaint seeks unspecified damages and other relief. On June 1, 2015, the Company filed two motions in response to Bard’s Complaint - one sought transfer to the District of Utah where the Utah Action is currently pending, and the other sought dismissal of the entire complaint on grounds that none of the claims in the asserted patents is directed to patent eligible subject matter under Section 101 of the Patent Statute and in light of recent authority from the U. S. Supreme Court.
31
On January 12, 2016, the Court issued a decision denying both motions. A Markman hearing was held on March 10, 2017 and the Court issued its Claim Construction Order on May 19, 2017. On May 19, 2017, Bard served its Final Infringement Contentions and on June 2, 2017, the Company served its Final Invalidity Contentions.
On October 20, 2017, the scheduling order for the case was amended to, among other things, set a trial date commencing July 23, 2018. The parties completed Expert Discovery in January 2018 and completed briefing on their respective case dispositive motions on April 27, 2018. On June 26, 2018, the Court denied all case dispositive motions, ruling that issues of material fact remained in dispute. On July 9, 2018, the Court continued the trial until March 2019. On January 9, 2019 the Court held a further claim construction hearing to resolve two outstanding claim construction issues prior to trial. A Report and Recommendation (by Magistrate-Judge Fallon) was issued on February 11, 2019 and entered by the Court on February 28, 2019. Jury selection was held on Friday March 1, 2019 and trial began on March 4, 2019.  On day four of the jury trial, at the close of C.R. Bard’s case, the Court granted the Company's oral motion for judgment as a matter of law under rule 50(a) as well as its motions for summary judgement on the grounds that the asserted patents are invalid, ineligible, not infringed and not willfully infringed.  On April 5, 2019, Bard filed a precautionary Notice of Appeal to the Federal Circuit. On April 26, 2019, the District Court issued a Memorandum and Order confirming the grant of judgment in the Company’s favor of patent ineligibility, non-infringement, patent invalidity and no willful infringement. Meanwhile, on May 10, 2019, the Company filed a Motion for Attorney fees and non-taxable expenses under 35 USC Sec. 285. On May 21, 2019, the Court issued a Memorandum and Order which, inter alia, stayed proceedings on the Company’s fee Motion and the Company’s equitable claims pending appeal; and entered Final Judgment on May 21, 2019 as well. Bard filed a second Notice of Appeal on May 23, 2019. Both appeals have since been consolidated and Bard’s opening brief was filed on September 27, 2019; the Company's answering brief was filed on January 15, 2020; and Bard’s reply brief was filed on March 4, 2020. A hearing was held on June 1, 2020, and the Company is currently awaiting a decision from the Federal Circuit . The Company maintains its belief that Bard’s claims are without merit. The Company has not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable.
AngioDynamics, Inc. v. C.R. Bard, Inc.
On May 30, 2017, the Company commenced an action in the United States District Court for the Northern District of New York entitled AngioDynamics, Inc. v. C.R. Bard, Inc. and Bard Access Systems, Inc. (“Bard”).  In this action, the Company alleges that Bard has illegally tied the sales of its tip location systems to the sales of its PICCs.  The Company alleges that this practice violates the federal antitrust laws and has had, and continues to have, an anti-competitive effect in the market for PICCs.  The Company seeks both monetary damages and injunctive relief. Bard moved to dismiss on September 8, 2017. On August 6, 2018 the court denied Bard’s motion in its entirety.  Discovery is largely complete, summary judgment, including all reply briefs, were fully briefed in October 2020, and the case will subsequently proceed to trial thereafter.
Merz North America Settlement
On May 16, 2019, Merz North America, Inc. (“Merz”) commenced an action in the United States District Court for the Southern District of New York entitled Merz North America, Inc. v. AngioDynamics, Inc.  In this action, Merz alleged breach of contract against AngioDynamics based on a March 1, 2016 Distribution Agreement.  On June 28, 2019, AngioDynamics reached a settlement with Merz. AngioDynamics made a lump-sum payment of $2.5 million to Merz in return for dismissal of the case with prejudice during the first quarter of fiscal year 2020.  The case was subsequently dismissed.
32
Item 1A. Risk Factors.
In addition to information set forth in this report, you should carefully consider the factors discussed in “Part I, Item 1A. Risk Factors” of our annual report on Form 10-K for our fiscal year ended May 31, 2020 which set forth information relating to important risks and uncertainties that could materially adversely affect our business, financial condition or operating results. You should review and consider such Risk Factors in making any investment decision with respect to our securities. An investment in our securities continues to involve a high degree of risk. There have been no material changes to the risk factors previously disclosed in our annual report on Form 10-K.

33
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
The following table provides information with respect to the shares of the Company’s common stock repurchased during the three months ended August 31, 2020:
Issuer Purchases of Equity Securities
Total
Number of
Shares
Purchased 		Average
Price Paid
per Share 		Total
Number of
Shares
Purchased
as Part of
Publicly
Announced
Programs (1) 		Maximum
Approximate
Dollar Value
of Shares
that May Yet
Be
Purchased
Under Plans
or Programs (1)
June 1, 2020 - June 30, 2020 —  $ 10.39  —  $ — 
July 1, 2020 - July 31, 2020 15,712  $ 9.49  —  $ — 
August 1, 2020 - August 31, 2020 —  $ 9.16  —  $ — 
Total 15,712  $ 9.49  —  — 
(1)These amounts are not applicable as the Company currently does not have a share repurchase program in effect.

Item 3. Defaults on Senior Securities.
None.
Item 4. Mine Safety Disclosures.
None.
Item 5. Other Information.
None.
34
Item 6
EXHIBIT INDEX
No.    Description
31.1
31.2
32.1
32.2
101.INS The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document
101.SCH XBRL Schema Document
101.CAL XBRL Calculation Linkbase Documents
101.DEF XBRL Taxonomy Extension Definition Linkbase Document
101.LAB XBRL Labels Linkbase Documents
101.PRE XBRL Presentation Linkbase Documents

35
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
ANGIODYNAMICS, INC.
(Registrant)
Date: October 7, 2020
/ S /    JAMES C. CLEMMER      
James C. Clemmer, President,
Chief Executive Officer
(Principal Executive Officer)
Date: October 7, 2020 / S /    STEPHEN A. TROWBRIDGE 
Stephen A. Trowbridge, Executive Vice President,
Chief Financial Officer
(Principal Financial and Accounting Officer)

36
AngioDynamics (NASDAQ:ANGO)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more AngioDynamics Charts.
AngioDynamics (NASDAQ:ANGO)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more AngioDynamics Charts.